Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
- 25 October 2014
- journal article
- phase i-studies
- Published by Springer Nature in Investigational New Drugs
- Vol. 33 (1) , 201-214
Abstract
Background This phase I/II study determined the maximal tolerable dose, dose limiting toxicities, antitumor activity, the pharmacokinetics and pharmacodynamics of ruthenium compound NAMI-A in combination with gemcitabine in Non-Small Cell Lung Cancer patients after first line treatment. Methods Initial dose escalation of NAMI-A was performed in a 28 day cycle: NAMI-A as a 3 h infusion through a port-a-cath at a starting dose of 300 mg/m2 at day 1, 8 and 15, in combination with gemcitabine 1,000 mg/m2 at days 2, 9 and 16. Subsequently, dose escalation of NAMI-A in a 21 day schedule was explored. At the maximal tolerable dose level of this schedule an expansion group was enrolled of which 15 patients were evaluable for response. Results Due to frequent neutropenic dose interruptions in the third week, the 28 day schedule was amended into a 21 day schedule. The maximal tolerable dose was 300 and 450 mg/m2 of NAMI-A (21 day schedule). Main adverse events consisted of neutropenia, anemia, elevated liver enzymes, transient creatinine elevation, nausea, vomiting, constipation, diarrhea, fatigue, and renal toxicity. Conclusion NAMI-A administered in combination with gemcitabine is only moderately tolerated and less active in NSCLC patients after first line treatment than gemcitabine alone.Keywords
This publication has 65 references indexed in Scilit:
- Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugsDalton Transactions, 2011
- Inhibition of B16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell InvasionThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Free Exchange across Cells, and Echistatin-Sensitive Membrane Target for the Metastasis Inhibitor NAMI-A (Imidazolium trans-Imidazole Dimethyl Sulfoxide Tetrachlororuthenate) on KB Tumor CellsThe Journal of Pharmacology and Experimental Therapeutics, 2005
- TGFβ1 regulation and collagen-release-independent connective tissue re-modelling by the ruthenium complex NAMI-A in solid tumoursJournal of Inorganic Biochemistry, 2004
- Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-AEuropean Journal of Cancer, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Binding of Antitumor Ruthenium(III) Complexes to Plasma ProteinsMetal-Based Drugs, 2000
- Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibitionChemico-Biological Interactions, 1995
- New Cisplatin Analogues in DevelopmentDrugs, 1993
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989